Build Your Comparison

Side-by-side financial analysis
TOI logo
TOI
OPCH logo
OPCH
KO logo
KO
MCK logo
MCK
CAH logo
CAH
Try popular comparisons:

Stock Comparison

TOI vs OPCH vs KO vs MCK vs CAH

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TOI
The Oncology Institute, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$5.41B
5Y Perf.-47.2%
OPCH
Option Care Health, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$3.25B
5Y Perf.+49.6%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+84.9%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$94.25B
5Y Perf.+411.0%
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$52.68B
5Y Perf.+328.9%

TOI vs OPCH vs KO vs MCK vs CAH — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TOI logoTOI
OPCH logoOPCH
KO logoKO
MCK logoMCK
CAH logoCAH
IndustryMedical - Care FacilitiesMedical - Care FacilitiesBeverages - Non-AlcoholicMedical - DistributionMedical - Distribution
Market Cap$5.41B$3.25B$355.61B$94.25B$52.68B
Revenue (TTM)$546M$5.67B$49.28B$403.43B$250.55B
Net Income (TTM)$-44M$206M$13.70B$4.76B$1.56B
Gross Margin14.8%18.0%61.7%3.6%3.7%
Operating Margin-6.0%5.9%29.3%1.6%0.9%
Forward P/E11.3x25.3x17.7x20.8x
Total Debt$104M$0.00$45.49B$8.61B$9.35B
Cash & Equiv.$34M$233M$10.27B$3.98B$3.87B

TOI vs OPCH vs KO vs MCK vs CAHLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TOI
OPCH
KO
MCK
CAH
StockJun 20Jun 26Return
The Oncology Instit… (TOI)10052.8-47.2%
Option Care Health,… (OPCH)100149.6+49.6%
The Coca-Cola Compa… (KO)100184.9+84.9%
McKesson Corporation (MCK)100511.0+411.0%
Cardinal Health, In… (CAH)100428.9+328.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: TOI vs OPCH vs KO vs MCK vs CAH

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: KO leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and dividend income and shareholder returns. The Oncology Institute, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. OPCH also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇KO emerged as the overall leader. Track its performance:
TOI
The Oncology Institute, Inc.
The Growth Play

TOI is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 27.8%, EPS growth 23.9%, 3Y rev CAGR 25.8%
  • 27.8% revenue growth vs CAH's -1.9%
  • +100.4% vs OPCH's -34.9%
Best for: growth exposure
OPCH
Option Care Health, Inc.
The Defensive Pick

OPCH ranks third and is worth considering specifically for sleep-well-at-night and defensive.

  • Lower volatility, beta 0.29, current ratio 1.53x
  • Beta 0.29, current ratio 1.53x
  • Lower P/E (11.3x vs 20.8x)
  • Beta 0.29 vs TOI's 1.95
Best for: sleep-well-at-night and defensive
KO
The Coca-Cola Company
The Income Pick

KO carries the broadest edge in this set and is the clearest fit for income & stability.

  • Dividend streak 56 yrs, beta -0.20, yield 2.5%
  • 27.8% margin vs TOI's -8.0%
  • 2.5% yield, 56-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
  • 13.1% ROA vs TOI's -26.5%, ROIC 15.8% vs -41.2%
Best for: income & stability
MCK
McKesson Corporation
The Long-Run Compounder

MCK is the clearest fit if your priority is long-term compounding.

  • 337.8% 10Y total return vs CAH's 211.1%
Best for: long-term compounding
CAH
Cardinal Health, Inc.
The Lower-Volatility Pick

Among these 5 stocks, CAH doesn't own a clear edge in any measured category.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthTOI logoTOI27.8% revenue growth vs CAH's -1.9%
ValueOPCH logoOPCHLower P/E (11.3x vs 20.8x)
Quality / MarginsKO logoKO27.8% margin vs TOI's -8.0%
Stability / SafetyOPCH logoOPCHBeta 0.29 vs TOI's 1.95
DividendsKO logoKO2.5% yield, 56-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
Momentum (1Y)TOI logoTOI+100.4% vs OPCH's -34.9%
Efficiency (ROA)KO logoKO13.1% ROA vs TOI's -26.5%, ROIC 15.8% vs -41.2%

TOI vs OPCH vs KO vs MCK vs CAH — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TOIThe Oncology Institute, Inc.
FY 2025
Health Care, Patient Service
49.5%$229M
Fee For Service
32.1%$149M
Capitated Revenue
17.4%$80M
Clinical Research Trials And Other Revenue
1.0%$5M
OPCHOption Care Health, Inc.
FY 2025
Reportable Segment
100.0%$5.6B
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B
MCKMcKesson Corporation
FY 2026
North American Pharmaceutical Segment
83.4%$336.7B
Oncology And Multispecialty Segment
12.0%$48.4B
Medical-Surgical Solutions Segment
2.9%$11.5B
Prescription Technology Solutions Segment
1.4%$5.8B
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
0.3%$1.0B
CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B

TOI vs OPCH vs KO vs MCK vs CAH — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKOLAGGINGCAH

Income & Cash Flow (Last 12 Months)

KO leads this category, winning 4 of 6 comparable metrics.

MCK is the larger business by revenue, generating $403.4B annually — 739.2x TOI's $546M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to TOI's -8.0%. On growth, TOI holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…KO logoKOThe Coca-Cola Com…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
RevenueTrailing 12 months$546M$5.7B$49.3B$403.4B$250.5B
EBITDAEarnings before interest/tax-$26M$406M$15.5B$7.1B$3.2B
Net IncomeAfter-tax profit-$44M$206M$13.7B$4.8B$1.6B
Free Cash FlowCash after capex-$26M$244M$12.6B$5.9B$4.4B
Gross MarginGross profit ÷ Revenue+14.8%+18.0%+61.7%+3.6%+3.7%
Operating MarginEBIT ÷ Revenue-6.0%+5.9%+29.3%+1.6%+0.9%
Net MarginNet income ÷ Revenue-8.0%+3.6%+27.8%+1.2%+0.6%
FCF MarginFCF ÷ Revenue-4.7%+4.3%+25.5%+1.5%+1.8%
Rev. Growth (YoY)Latest quarter vs prior year+41.2%+1.3%+12.1%+6.0%+11.0%
EPS Growth (YoY)Latest quarter vs prior year+90.5%+3.6%+18.2%+37.0%-19.5%
KO leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

OPCH leads this category, winning 4 of 6 comparable metrics.

At 16.3x trailing earnings, OPCH trades at a 53% valuation discount to CAH's 34.7x P/E. On an enterprise value basis, OPCH's 7.4x EV/EBITDA is more attractive than KO's 26.4x.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…KO logoKOThe Coca-Cola Com…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Market CapShares × price$5.4B$3.2B$355.6B$94.2B$52.7B
Enterprise ValueMkt cap + debt − cash$5.5B$3.0B$390.8B$98.9B$58.1B
Trailing P/EPrice ÷ TTM EPS-9.83x16.35x27.18x20.43x34.71x
Forward P/EPrice ÷ next-FY EPS est.11.31x25.27x17.72x20.79x
PEG RatioP/E ÷ EPS growth rate2.43x
EV / EBITDAEnterprise value multiple7.38x26.39x13.77x18.97x
Price / SalesMarket cap ÷ Revenue10.75x0.57x7.42x0.23x0.24x
Price / BookPrice ÷ Book value/share2.56x10.40x
Price / FCFMarket cap ÷ FCF12.57x67.15x16.48x28.47x
OPCH leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

Evenly matched — KO and MCK each lead in 3 of 8 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $15 for OPCH. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs TOI's 4/9, reflecting strong financial health.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…KO logoKOThe Coca-Cola Com…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
ROE (TTM)Return on equity+15.3%+41.1%
ROA (TTM)Return on assets-26.5%+6.0%+13.1%+5.7%+2.8%
ROICReturn on invested capital-41.2%+15.3%+15.8%+2.5%+33.8%
ROCEReturn on capital employed-33.7%+12.8%+17.3%+44.8%+19.2%
Piotroski ScoreFundamental quality 0–945776
Debt / EquityFinancial leverage1.33x
Net DebtTotal debt minus cash$70M-$233M$35.2B$4.6B$5.5B
Cash & Equiv.Liquid assets$34M$233M$10.3B$4.0B$3.9B
Total DebtShort + long-term debt$104M$0$45.5B$8.6B$9.3B
Interest CoverageEBIT ÷ Interest expense-4.96x5.50x10.70x51.78x6.38x
Evenly matched — KO and MCK each lead in 3 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

TOI leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $41,299 today (with dividends reinvested), compared to $5,257 for TOI. Over the past 12 months, TOI leads with a +100.4% total return vs OPCH's -34.9%. The 3-year compound annual growth rate (CAGR) favors TOI at 111.1% vs OPCH's -11.6% — a key indicator of consistent wealth creation.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…KO logoKOThe Coca-Cola Com…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
YTD ReturnYear-to-date+44.7%-35.6%+20.3%-4.6%+9.3%
1-Year ReturnPast 12 months+100.4%-34.9%+17.2%+7.7%+40.7%
3-Year ReturnCumulative with dividends+841.3%-30.9%+47.0%+100.5%+163.7%
5-Year ReturnCumulative with dividends-47.4%+1.1%+65.6%+313.0%+300.9%
10-Year ReturnCumulative with dividends-45.3%+127.6%+121.1%+337.8%+211.1%
CAGR (3Y)Annualised 3-year return+111.1%-11.6%+13.7%+26.1%+38.2%
TOI leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than TOI's 1.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs OPCH's 56.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…KO logoKOThe Coca-Cola Com…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Beta (5Y)Sensitivity to S&P 5001.95x0.29x-0.20x-0.10x-0.07x
52-Week HighHighest price in past year$5.58$36.80$84.04$999.00$233.60
52-Week LowLowest price in past year$2.02$18.01$65.35$637.00$137.75
% of 52W HighCurrent price vs 52-week peak+95.2%+56.4%+98.3%+78.5%+95.8%
RSI (14)Momentum oscillator 0–10065.344.160.655.574.4
Avg Volume (50D)Average daily shares traded1.6M3.2M12.7M879K1.9M
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

KO leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: TOI as "Buy", OPCH as "Buy", KO as "Buy", MCK as "Buy", CAH as "Buy". Consensus price targets imply 50.7% upside for TOI (target: $8) vs 4.2% for KO (target: $86). For income investors, KO offers the higher dividend yield at 2.46% vs MCK's 0.39%.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…KO logoKOThe Coca-Cola Com…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$8.00$31.22$86.13$994.86$253.38
# AnalystsCovering analysts514483133
Dividend YieldAnnual dividend ÷ price+2.5%+0.4%+0.9%
Dividend StreakConsecutive years of raises1561840
Dividend / ShareAnnual DPS$2.04$3.07$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%+9.5%+0.2%+5.0%+1.5%
KO leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

KO leads in 3 of 6 categories (Income & Cash Flow, Risk & Volatility). OPCH leads in 1 (Valuation Metrics). 1 tied.

Best OverallThe Coca-Cola Company (KO)Leads 3 of 6 categories
Loading custom metrics...

TOI vs OPCH vs KO vs MCK vs CAH: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is TOI or OPCH or KO or MCK or CAH a better buy right now?

For growth investors, The Oncology Institute, Inc.

(TOI) is the stronger pick with 27. 8% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). Option Care Health, Inc. (OPCH) offers the better valuation at 16. 3x trailing P/E (11. 3x forward), making it the more compelling value choice. Analysts rate The Oncology Institute, Inc. (TOI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — TOI or OPCH or KO or MCK or CAH?

On trailing P/E, Option Care Health, Inc.

(OPCH) is the cheapest at 16. 3x versus Cardinal Health, Inc. at 34. 7x. On forward P/E, Option Care Health, Inc. is actually cheaper at 11. 3x.

03

Which is the better long-term investment — TOI or OPCH or KO or MCK or CAH?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +313.

0%, compared to -47. 4% for The Oncology Institute, Inc. (TOI). Over 10 years, the gap is even starker: MCK returned +337. 8% versus TOI's -45. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — TOI or OPCH or KO or MCK or CAH?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus The Oncology Institute, Inc. 's 1. 95β — meaning TOI is approximately -1074% more volatile than KO relative to the S&P 500.

05

Which is growing faster — TOI or OPCH or KO or MCK or CAH?

By revenue growth (latest reported year), The Oncology Institute, Inc.

(TOI) is pulling ahead at 27. 8% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to 3. 3% for Option Care Health, Inc.. Over a 3-year CAGR, TOI leads at 25. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — TOI or OPCH or KO or MCK or CAH?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -12. 1% for The Oncology Institute, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -7. 2% for TOI. At the gross margin level — before operating expenses — KO leads at 61. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is TOI or OPCH or KO or MCK or CAH more undervalued right now?

On forward earnings alone, Option Care Health, Inc.

(OPCH) trades at 11. 3x forward P/E versus 25. 3x for The Coca-Cola Company — 14. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TOI: 50. 7% to $8. 00.

08

Which pays a better dividend — TOI or OPCH or KO or MCK or CAH?

In this comparison, KO (2.

5% yield), CAH (0. 9% yield), MCK (0. 4% yield) pay a dividend. TOI, OPCH do not pay a meaningful dividend and should not be held primarily for income.

09

Is TOI or OPCH or KO or MCK or CAH better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). The Oncology Institute, Inc. (TOI) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, TOI: -45. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between TOI and OPCH and KO and MCK and CAH?

These companies operate in different sectors (TOI (Healthcare) and OPCH (Healthcare) and KO (Consumer Defensive) and MCK (Healthcare) and CAH (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TOI is a small-cap high-growth stock; OPCH is a small-cap deep-value stock; KO is a large-cap quality compounder stock; MCK is a mid-cap quality compounder stock; CAH is a mid-cap quality compounder stock. KO, CAH pay a dividend while TOI, OPCH, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.